|
|
|
|
|
| August 19,
2010 | ISSUE NUMBER 162 VOL 8 |
R&D
Lilly Kills Two Alzheimer's Trials
In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse.
Advertisement:
Capgemini
Are You Really Closing the Loop?
There is a considerable advantage to being one of the first companies in pharma to successfully close the loop and pave the way to a new commercial model that puts the customer first. However, implementing comprehensive, closed-loop marketing has proven difficult for many in our industry. Capgemini Consulting examines the functional implications for implementing closed-loop marketing across the commercial organization and the hurdles to overcome to fully close the loop. Click here
|
FDA
Shire to Pull ProAmatine After FDA Calls for Withdrawal
Nearly 14 years after its approval, FDA is calling for midodrine hydrochloride to be withdrawn from the market due to lack of followup trial data. Shire jumps the gun and pulls ProAmatine from the market.
Social Media
Patients Want to Talk. Do You?
Why are companies rushing to the web when traditional engagement with patient groups remains so underexploited, asks Jacky Law.
New & Noteworthy
Augmented Reality: Improving New Media Capabilities
New strategies such as augmented reality can increase patient compliance and knowledge.
|
| 
|
 // Cornerstone Pharmaceuticals appointed Dorit Arad director of research and development for its Israeli operations. // Amarin named Colin W. Stewart president and CEO.
// US Oncology added John Osborn as executive vice president and general counsel, and Asif Ahmad as executive vice president of technology services. // Darl Moreland joined Alexza Pharmaceuticals as vice president, quality.
// Pinnacle Biologics appointed James L. Foght to the board of directors.
// WuXi PharmaTech named Edward Hu chief financial officer. // |
| |
Advertisement:
CBI
CBI's Forum on Strategic Pipeline Planning - September 28-29, 2010, Princeton, NJ Balance Internal and External Investment Opportunities to Meet Short- and Long-Term Planning Objectives. Industry thought leaders from Allergan, AstraZeneca, BMS, GSK, J&J, MannKind, Merck and more! Register at  www.cbinet.com/pipelineplanning by August 31, 2010 and save $300 with promo code GQM796.
|
|
| |
|
Release Higher Performance Through Business Analytics
Wednesday, Sept. 22, 11 A.M. Eastern; 8 A.M. Pacific
Register Free at http://pharmexec.com/analytics
3-D Segmentation: Managing your Brand’s Three Most Important Influencers
Thursday, Oct. 7, at 12 P.M. Eastern; 9 A.M. Pacific
Register Free at http://pharmexec.com/geo |
|
|
Sep 9–10 Clinical Trials in Latin America
Lima, Peru
Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC
Dec 8—9 CMAC 2010 - Commercialization and Market Access Congress
Orlando, FL
|
|
|
|
 |
|
 |
|
 |
| A year and a half into President Obama's tenure, how do you view the effectiveness of the "new" FDA? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
